Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-98768111 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical trial participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment.
High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT. Other DLT criteria includes any related toxicity resulting in permanent treatment discontinuation or a delay in dose administration greater than (\>)14 days and any death not clearly due to the underlying disease or non-trial intervention-related causes.
| Arm | Type | Description |
|---|---|---|
| JNJ-98768111 | EXPERIMENTAL | Participants in Part 1 of the study will receive escalating doses of JNJ-98768111 to identify the putative recommended phase 2 dose (pRP2D) regimen(s). Participants in Part 2 of the study will receive JNJ-98768111 at the pRP2D regimen(s) determined in Part 1. |
| Name | Type | Description |
|---|---|---|
| JNJ-98768111 | DRUG | JNJ-98768111 will be administered intravenously. |
Inclusion criteria: * a. Histologically confirmed adenocarcinoma of the prostate. Adenocarcinoma with small cell or neuroendocrine features is permitted. b. Measurable or evaluable disease (metastatic prostate cancer) based on computed tomography (CT), magnetic resonance imaging (MRI), or bone scan...
JNJ-98768111 is an investigational small molecule being studied for the treatment of advanced prostate cancer, specifically prostatic neoplasms. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities.
JNJ-98768111 is being developed by Johnson & Johnson, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ.
JNJ-98768111 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 1 trial is currently recruiting participants.
JNJ-98768111 is being evaluated in a Phase 1 clinical trial with the identifier NCT07746713, titled 'A Study of JNJ-98768111 in Participants With Advanced Prostate Cancer.' The trial is recruiting male participants aged 18 years and older in the United States, with a target enrollment of 100 participants.
No alternative names for JNJ-98768111 have been disclosed. The drug is identified solely by its development code JNJ-98768111 in clinical trial registries and company communications.